Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Bioaffinity Technologies WT (BIAFW)

Bioaffinity Technologies WT (BIAFW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
bioAffinity Technologies’ Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation Business Wire - Wed Jan 7, 7:00AM CST

CyPath® Lung addresses urgent unmet need in projected $10.4 billion lung cancer diagnostic market by 2034 Precision Pathology Laboratory Services meets...

BIAF : 1.2500 (-1.57%)
BIAFW : 0.2819 (+9.77%)
bioAffinity Technologies’ Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable Business Wire - Wed Dec 3, 2025

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) , a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced...

BIAF : 1.2500 (-1.57%)
BIAFW : 0.2819 (+9.77%)
bioAffinity Technologies Reports Third Quarter 2025 Financial Results Business Wire - Fri Nov 14, 2025

Company achieves 86% increase in CyPath® Lung testing revenue, strengthens balance sheet

BIAF : 1.2500 (-1.57%)
BIAFW : 0.2819 (+9.77%)
bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases Business Wire - Tue Oct 28, 2025

Australian patent strengthens global patent portfolio

BIAF : 1.2500 (-1.57%)
BIAFW : 0.2819 (+9.77%)
bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025 Business Wire - Mon Oct 20, 2025

Visit the CyPath® Lung team at Booth #2242 October 19-22

BIAF : 1.2500 (-1.57%)
BIAFW : 0.2819 (+9.77%)
bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer Business Wire - Thu Oct 16, 2025

U.S. award protects AI-built platform and adds to growing international patent portfolio

BIAF : 1.2500 (-1.57%)
BIAFW : 0.2819 (+9.77%)
bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements Business Wire - Wed Oct 15, 2025

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung , the Company’s...

BIAF : 1.2500 (-1.57%)
BIAFW : 0.2819 (+9.77%)
WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules PR Newswire - Thu Oct 9, 2025

JERSEY CITY, N.J. , Oct. 9, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies,...

BIAF : 1.2500 (-1.57%)
BIAFW : 0.2819 (+9.77%)
bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules Business Wire - Thu Oct 9, 2025

bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced...

BIAF : 1.2500 (-1.57%)
BIAFW : 0.2819 (+9.77%)
WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules PR Newswire - Wed Oct 8, 2025

JERSEY CITY, N.J. , Oct. 8, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies,...

BIAF : 1.2500 (-1.57%)
BIAFW : 0.2819 (+9.77%)

Barchart Exclusives

Should You Buy Dividend-Paying Gold Stocks as Trump Makes Them ‘Great Again’? Barchart - Tue Jan 13, 6:30PM CST
Gold stocks have soared over the last year amid the rally in gold prices. Miners are paying handsome dividends as their cash flows have tracked gold prices higher. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot